SCHEMBL2073469

SCHEMBL2073469

Nc1ccc2c(c1)nc(C(F)(F)F)n2CCN1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 2/20 0.42
KDM4E B2RXH2 4/20 0.41
RAD52 P43351 1/20 0.41
BCHE P06276 2/20 0.39
CNR2 P34972 2/20 0.39
CNR1 P21554 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.37
OPRK1 P41145 2/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
KLK7 P49862 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2075533 0.80 KMT2A (0.56) HTTL3MBTL1BCHECNR2CNR1
SCHEMBL13358850 0.78 KDM4E (0.61) HTTKDM4ERAD52ALDH1A1GAA
SCHEMBL5521319 0.78 CNR2 (0.45) HTTKDM4ERAD52BCHECNR2
SCHEMBL5419669 0.73 KDM4E (0.44) HTTPOLBKDM4ERAD52ALDH1A1
SCHEMBL13605817 0.72 NPSR1 (0.44) L3MBTL1POLBCNR2MAPT
SCHEMBL13605820 0.72 CNR2 (0.42) CNR2
SCHEMBL4968387 0.69 MEN1 (0.41) HTTKDM4EBCHECNR2CNR1
SCHEMBL2074890 0.69 BRPF1 (0.44) L3MBTL1POLBKDM4ERAD52BCHE
SCHEMBL2075907 0.69 HSD17B10 (0.68) KDM4EBCHECNR2CNR1ALDH1A1
SCHEMBL24041880 0.68 CNR2 (0.43) HTTPOLBKDM4ECNR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R HTT 181/4885L3MBTL1 646/4885POLB 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.